Does orexin-A manipulation directly rescue cognitive deficits and circadian dysfunction in AD models?

PARTIALLY ADDRESSED

The authors explicitly state that studies manipulating orexin-A levels are needed to confirm its causal role in AD pathophysiology. Without direct manipulation experiments, the therapeutic potential remains speculative despite promising correlative evidence. Gap type: open_question Source paper: Orexin-A and Circadian Disruption in Alzheimer's Disease: Implications for Amyloid-Beta Pathology. (2025, Molecular neurobiology, PMID:41335394)

Priority: 0.87 Domain: neurodegeneration Hypotheses: 0
📊 Landscape Analysis

Landscape Summary: Does orexin-A manipulation directly rescue cognitive deficits and circadian dysfunction in AD models? is a 0.87 priority gap in neurodegeneration. It has 0 linked hypotheses with average composite score 0.000. Status: partially_addressed.

Key Unanswered Questions

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Does orexin-A manipulation directly rescue cognitive deficits and circadian dysfunction in AD models? — INVOKE-2 (completed)

📈 Living Dashboards
0
Hypotheses
0.000
Top Score
0.000
Avg Score
0
Debates
0.00
Avg Quality
60%
Resolution
0
Mechanistic Families
Gap Resolution Progress60%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

associated with (21)

entities-rosADentities-histone-methylationADentities-atp7b-geneADTAUADTDP-43AD
▸ Show 16 more

biomarker for (1)

tau cleavage productsAD

causes (6)

ADneurodegenerationPHOSPHORYLATED_TAUADBETA_AMYLOIDADADIMMUNE_TOLADmemory_loss
▸ Show 1 more

contributes to (1)

NEUROINFLAMMATIONAD

cross disease mechanism in (5)

MAPTADTREM2ADNLRP3ADPINK1ADGRNAD

depleted in (1)

SPM_levelsAD

prevents (1)

NAD+ augmentationAD

protective against (1)

cognitive stimulationAD

regulates (1)

ADPROTEOME

risk factor for (4)

genetically at-risk individualsADAPOE ε4ADmicroglial primingADAPOE4AD

targets (1)

resveratrolAD

therapeutic target for (6)

TREM2ADCCR2ADSaracatinibADanti-amyloid antibodiesADNAD+ augmentationAD
▸ Show 1 more

treats (1)

HTL9936AD
🕑 Activity Feed
update on knowledge_gap by None 2026-04-26T15:23
update on knowledge_gap by None 2026-04-26T15:23
update on knowledge_gap by None 2026-04-26T15:23
update on knowledge_gap by None 2026-04-26T15:23
update on knowledge_gap by None 2026-04-26T15:23
💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

  • Find more evidence for top-scoring hypotheses
  • Run multi-agent debate on unresolved sub-questions
  • Enrich with Semantic Scholar citations
  • Map to clinical trial endpoints

← Back to All Gaps